Acumen Pharmaceuticals, Inc. (ABOS)
2.30
+0.06
(+2.68%)
USD |
NASDAQ |
Sep 28, 16:00
2.30
0.00 (0.00%)
After-Hours: 20:00
Acumen Pharmaceuticals Enterprise Value : 83.43M for Sept. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 83.43M |
| September 24, 2026 | 83.07M |
| September 23, 2026 | 88.13M |
| September 22, 2026 | 113.08M |
| September 21, 2026 | 108.74M |
| September 18, 2026 | 113.08M |
| September 17, 2026 | 107.30M |
| September 16, 2026 | 110.19M |
| September 15, 2026 | 130.44M |
| September 14, 2026 | 123.21M |
| September 11, 2026 | 132.61M |
| September 10, 2026 | 128.27M |
| September 09, 2026 | 127.55M |
| September 08, 2026 | 149.96M |
| September 04, 2026 | 151.41M |
| September 03, 2026 | 144.90M |
| September 02, 2026 | 145.62M |
| September 01, 2026 | 132.61M |
| August 31, 2026 | 127.55M |
| August 28, 2026 | 132.61M |
| August 27, 2026 | 140.56M |
| August 26, 2026 | 137.67M |
| August 25, 2026 | 145.62M |
| August 24, 2026 | 143.82M |
| August 21, 2026 | 149.96M |
| Date | Value |
|---|---|
| August 20, 2026 | 152.13M |
| August 19, 2026 | 149.24M |
| August 18, 2026 | 119.59M |
| August 17, 2026 | 113.81M |
| August 14, 2026 | 114.53M |
| August 13, 2026 | 105.85M |
| August 12, 2026 | 102.96M |
| August 11, 2026 | 100.07M |
| August 10, 2026 | 97.17M |
| August 07, 2026 | 97.90M |
| August 06, 2026 | 86.33M |
| August 05, 2026 | 83.43M |
| August 04, 2026 | 83.43M |
| August 03, 2026 | 79.10M |
| July 31, 2026 | 76.93M |
| July 30, 2026 | 78.37M |
| July 29, 2026 | 74.03M |
| July 28, 2026 | 86.33M |
| July 27, 2026 | 80.54M |
| July 24, 2026 | 75.48M |
| July 23, 2026 | 78.37M |
| July 22, 2026 | 81.26M |
| July 21, 2026 | 82.71M |
| July 20, 2026 | 81.26M |
| July 17, 2026 | 84.16M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Biogen, Inc. | 40.69B |
| ACADIA Pharmaceuticals, Inc. | 2.677B |
| Alnylam Pharmaceuticals, Inc. | 33.91B |
| Anika Therapeutics, Inc. | 259.45M |
| Savara, Inc. | 884.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.72M |
| Total Expenses (Quarterly) | 32.72M |
| EPS Diluted (Quarterly) | -0.4528 |
| Earnings Yield | -70.98% |
| Normalized Earnings Yield | -70.83 |